<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05797883</url>
  </required_header>
  <id_info>
    <org_study_id>HL-ZY-002</org_study_id>
    <nct_id>NCT05797883</nct_id>
  </id_info>
  <brief_title>FOLFOX/FOLFIRI Containing Levofolinic Acid (Zuoyu ®) in the Treatment of Unresectable or Metastatic Colorectal Cancer</brief_title>
  <official_title>Clinical Study on the Efficacy and Safety of FOLFOX/FOLFIRI± Targeted Drug Regimen Containing Levofolinic Acid (Zuoyu ®) in the Treatment of Unresectable or Metastatic Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>China Medical University, China</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>China Medical University, China</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To observe and evaluate the efficacy and safety of FOLFOX/FOLFIRI± target-directed regimen&#xD;
      containing Levofolinic Acid (Zuoyu ®) in first-line treatment of unresectable or metastatic&#xD;
      colorectal cancer&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2022</start_date>
  <completion_date type="Anticipated">December 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>2 years</time_frame>
    <description>The proportion of patients whose best overall response (BOR) is complete response (CR) or partial response (PR) assessed by iRECIST v1.1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>2years</time_frame>
    <description>The date from random to the first occurrence of disease progression or death from any cause, whichever comes first</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR)</measure>
    <time_frame>2years</time_frame>
    <description>The proportion of patients whose BOR is CR, PR, and stable disease (SD) assessed</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Unresectable or Metastatic Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>FOLFOX/FOLFIRI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>q2w, after 8 cycles of medication or patient intolerance or disease progression;</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FOLFOX/FOLFIRI</intervention_name>
    <description>mFOLFOX6 ：oxaliplatin 85mg/m² IV infusion 2h d1, 5-FU 400mg/m² push d1, Then 5-FU 1200mg/(m2▪d)×2d+Levofolinic Acid 200mg/m² continuous mixed infusion for 46-48h (total 5-FU 2400mg/m²); FOLFIRI ：Irinotecan 180mg/m ² static pulse infusion 30min~90min d1, 5-FU 400mg/m² push d1, Then 5-FU 1200mg/(m2▪d)×2d+ Levofolinic Acid 200mg/m² continuous mixed infusion for 46-48h (total 5-FU 2400mg/m²); The combination of cetuximab/bevacizumab and other targeted agents depends on the patient.</description>
    <arm_group_label>FOLFOX/FOLFIRI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female, ≥18 years old;&#xD;
&#xD;
          -  Patients with histopathologically confirmed unresectable or metastatic colorectal&#xD;
             cancer who have not previously received chemotherapy or targeted therapy for&#xD;
             unresectable or metastatic lesions;&#xD;
&#xD;
          -  Have at least one measurable lesion according to RECIST 1.1 standards;&#xD;
&#xD;
          -  ECOG PS score: 0-2;&#xD;
&#xD;
          -  Expected survival greater than 3 months;&#xD;
&#xD;
          -  Routine blood routine, liver and kidney function, electrocardiogram and other routine&#xD;
             tests were basically normal, no contraindications of chemotherapy;&#xD;
&#xD;
          -  The subjects voluntarily joined the study, signed the informed consent, had good&#xD;
             compliance, and cooperated with follow-up visits;&#xD;
&#xD;
          -  Researchers believe treatment can benefit.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  A proven allergy to the test drug and/or its excipients;&#xD;
&#xD;
          -  Pregnant or lactating women;&#xD;
&#xD;
          -  Patients judged by the investigator to be unsuitable for inclusion in this study;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jingdong Zhang</last_name>
    <phone>+86-13804027878</phone>
    <email>zhangjingdong@cancerhosp-ln-cmu.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Qian Dong</last_name>
    <email>dongqian08@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Liaoning Cancer Hospital &amp; Institute</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <zip>110042</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qian Dong, Doctor</last_name>
      <phone>17309815028</phone>
      <email>dongqian08@163.com</email>
    </contact>
    <investigator>
      <last_name>Jingdong Zhang, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2023</verification_date>
  <study_first_submitted>March 22, 2023</study_first_submitted>
  <study_first_submitted_qc>March 22, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">April 4, 2023</study_first_posted>
  <last_update_submitted>March 22, 2023</last_update_submitted>
  <last_update_submitted_qc>March 22, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">April 4, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>China Medical University, China</investigator_affiliation>
    <investigator_full_name>Jingdong Zhang</investigator_full_name>
    <investigator_title>Chief physician</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

